US 12,239,765 B2
Amorphous silicon oxide, amorphous silicon oxynitride, and amorphous silicon nitride thin films and uses thereof
Venu Varanasi, Lewisville, TX (US); Pranesh Aswath, Grapevine, TX (US); Megen Maginot, Beeville, TX (US); and Nickolay V. Lavrik, Knoxville, TN (US)
Assigned to THE TEXAS A&M UNIVERSITY SYSTEM, College Station, TX (US); UT- BATTELLE, LLC, Oak Ridge, TN (US); and BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US)
Filed by THE TEXAS A&M UNIVERSITY SYSTEM, College Station, TX (US); BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US); and UT- BATTELLE, LLC, Oak Ridge, TN (US)
Filed on Nov. 12, 2020, as Appl. No. 17/096,390.
Application 17/096,390 is a division of application No. 14/848,107, filed on Sep. 8, 2015, granted, now 10,898,618.
Claims priority of provisional application 62/047,421, filed on Sep. 8, 2014.
Prior Publication US 2021/0138120 A1, May 13, 2021
Int. Cl. A61L 31/08 (2006.01); A61L 31/16 (2006.01); C23C 16/02 (2006.01); C23C 16/30 (2006.01); C23C 16/40 (2006.01)
CPC A61L 31/088 (2013.01) [A61L 31/16 (2013.01); C23C 16/0281 (2013.01); C23C 16/308 (2013.01); C23C 16/401 (2013.01); A61L 2300/102 (2013.01); A61L 2300/412 (2013.01); A61L 2400/18 (2013.01); A61L 2420/02 (2013.01); A61L 2430/02 (2013.01)] 8 Claims
OG exemplary drawing
 
1. A method for enhancing bone formation at a surface comprising:
providing a surface with an amorphous silica-based overlay using a PECVD method to provide a treated surface having an elemental surface-O—Si interface, wherein said amorphous silica-based overlay comprises a first layer adjacent to the surface, the first layer comprising an amorphous silicon oxide (SiOx) and a second layer atop the first layer, the second layer comprising amorphous nitrogen enriched silicon oxide (SiONx), wherein the amorphous silica-based overlay releases Si-ion from said bone-treated surface interface;
providing said treated surface to a bone to create a bone-treated surface interface;
exposing said bone-treated surface interface to a population of cells comprising osteoblasts or osteoblast progenitor cells, in an aqueous environment comprising an osteogenic media to provide for enhanced bioactivity; and
enhancing bone formation at said treated surface,
wherein release of Si-ion at the bone-treated surface interface reduces reactive oxygen species levels at said bone-treated surface interface by enhancing osteoblast production of anti-oxidant species.